BridgeBio Pharma Cash on Hand 2018-2024 | BBIO
BridgeBio Pharma cash on hand from 2018 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
BridgeBio Pharma Annual Cash on Hand
(Millions of US $) |
| 2023 |
$452 |
| 2022 |
$510 |
| 2021 |
$837 |
| 2020 |
$607 |
| 2019 |
$546 |
| 2018 |
$436 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Cash on Hand
(Millions of US $) |
| 2024-09-30 |
$406 |
| 2024-06-30 |
$587 |
| 2024-03-31 |
$520 |
| 2023-12-31 |
$452 |
| 2023-09-30 |
$560 |
| 2023-06-30 |
$404 |
| 2023-03-31 |
$517 |
| 2022-12-31 |
$510 |
| 2022-09-30 |
$592 |
| 2022-06-30 |
$716 |
| 2022-03-31 |
$671 |
| 2021-12-31 |
$837 |
| 2021-09-30 |
$600 |
| 2021-06-30 |
$838 |
| 2021-03-31 |
$919 |
| 2020-12-31 |
$607 |
| 2020-09-30 |
$711 |
| 2020-06-30 |
$841 |
| 2020-03-31 |
$905 |
| 2019-12-31 |
$546 |
| 2019-09-30 |
$536 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.426B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
